Skip to main content
Journal cover image

Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants.

Publication ,  Journal Article
Yue, J; LeSon, CE; Rimland, CA; Brodeur, K; Weng, R; Hsu, EE; Lam, MT; Meyer, M; Okada, S; Hsu, ALD; Alhezam, MA; Perron, MM; Halyabar, O ...
Published in: Arthritis Rheumatol
October 28, 2025

OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. METHODS: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. RESULTS: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant-negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). CONCLUSION: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.

Duke Scholars

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

October 28, 2025

Location

United States

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yue, J., LeSon, C. E., Rimland, C. A., Brodeur, K., Weng, R., Hsu, E. E., … Lee, P. Y. (2025). Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants. Arthritis Rheumatol. https://doi.org/10.1002/art.43412
Yue, Jian, Courtney E. LeSon, Casey A. Rimland, Kailey Brodeur, Rachel Weng, Evan E. Hsu, Michael T. Lam, et al. “Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants.Arthritis Rheumatol, October 28, 2025. https://doi.org/10.1002/art.43412.
Yue J, LeSon CE, Rimland CA, Brodeur K, Weng R, Hsu EE, et al. Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants. Arthritis Rheumatol. 2025 Oct 28;
Yue, Jian, et al. “Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants.Arthritis Rheumatol, Oct. 2025. Pubmed, doi:10.1002/art.43412.
Yue J, LeSon CE, Rimland CA, Brodeur K, Weng R, Hsu EE, Lam MT, Meyer M, Okada S, Hsu ALD, Alhezam MA, Perron MM, Halyabar O, Dedeoglu F, Nigrovic PA, Shimamura A, Rowe RG, Cooper MA, Vogel TP, Gillispie-Taylor M, Peterson R, Lin C, Nowicki KD, Dollerschell K, Nakano TA, Labrosse R, Cochino A-V, Ioan A, Mendonca LO, Barros SF, Kalil J, Rojas JP, Kuan AD, Sobel ES, Moussa T, Lee SSM, Koh LW, Khan A, Sutnga S, Khubchandani R, Shoman W, El Chazli Y, Pinto B, Kavadichanda C, Abraham RS, Sun X, Zhou Q, Naidu G, Sharma A, Esperanzate C, Kastner DL, Aksentijevich I, Kelly SJ, Hershfield M, Tarrant TK, Lee PY. Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants. Arthritis Rheumatol. 2025 Oct 28;
Journal cover image

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

October 28, 2025

Location

United States

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences